HIV/AIDS Survival Outcomes in China: A New Study from Chongqing

Strategic Insights -

Despite expanded access to antiretroviral therapy in China, AIDS remains a significant public health challenge. A recent study aimed to assess survival outcomes and identify factors influencing survival time among HIV/AIDS patients receiving antiretroviral therapy in Jiulongpo District, Chongqing. The research utilized data from 2012 to 2022 and employed life tables, Kaplan-Meyer analysis, and accelerated failure time modeling to analyze the data. The study's findings have significant implications for improving the long-term outcomes of people living with HIV.

Key Takeaways:

  • The study found that the 1-, 3-, 5-, and 10-year cumulative survival rates were 94% (95% CI: 0.93 to 0.95), 90% (95% CI: 0.89 to 0.91), 86% (95% CI: 0.85 to 0.87), and 79% (95% CI: 0.76 to 0.81), respectively.
  • Patients aged 30-49 had a significantly longer survival time compared to those aged 15-29 (TR = 0.22, 95% CI: 0.11 to 0.46).
  • The study concluded that identifying factors influencing survival time among HIV/AIDS patients receiving antiretroviral therapy is crucial for improving their long-term outcomes.
  • The research highlighted the importance of targeted interventions and clinical decision-making in improving the survival rates of HIV/AIDS patients.
  • The study suggests that antiretroviral therapy coverage has improved in China, but more work is needed to address the ongoing public health challenge posed by AIDS.

Statistics:

  • 94% cumulative survival rate at 1-year (95% CI: 0.93 to 0.95)
  • 79% cumulative survival rate at 10-year (95% CI: 0.76 to 0.81)
  • Significantly longer survival time for patients aged 30-49 compared to those aged 15-29 (TR = 0.22, 95% CI: 0.11 to 0.46)

Sources:

  • Survival analysis and factors influencing survival time of adult HIV/AIDS patients receiving antiretroviral therapy from 2012 to 2022 in Chongqing, China: a retrospective cohort study (2025;13:1614619, Frontiers in Public Health)
  • NewsRx (2025, October 20). Reports Outline HIV/AIDS Study Findings from Disease Control and Prevention Center (Survival analysis and factors influencing survival time of adult HIV/AIDS patients receiving antiretroviral therapy from 2012 to 2022 in Chongqing, China: a ...). AIDS Weekly, p 349.